BDBM633927 US11807649, Compound 19::US11807649, Compound 2

SMILES Cc1cc(Nc2ncnc3cc4OC[C@H]5CN(CCN5C(=O)C=C)c4nc23)ccc1Oc1ccn2ncnc2c1

InChI Key InChIKey=LAAGQYGQCANRRA-UHFFFAOYSA-N

Data  8 IC50

  Tab Delimited (TSV)   2D SDfile   Computed 3D by Vconf -m prep SDfile
Find this compound or compounds like it in BindingDB:
   Substructure
Similarity at least:  must be >=0.5
Exact match

Activity Spreadsheet -- Enzyme Inhibition Constant Data from BindingDB

Found 8 hits for monomerid = 633927   

TargetReceptor tyrosine-protein kinase erbB-2(Human)
Enliven Therapeutics

US Patent
LigandPNGBDBM633927(US11807649, Compound 2 | US11807649, Compound 19)
Affinity DataIC50: 9.77nMAssay Description:Table B3: Enzyme-linked immunosorbent assays (ELISA) were performed to measure phosphorylated ERBB2 levels. A capture antibody able to detect phospho...More data for this Ligand-Target Pair
In Depth
Date in BDB:
1/19/2024
Entry Details
US Patent

TargetReceptor tyrosine-protein kinase erbB-2(Human)
Enliven Therapeutics

US Patent
LigandPNGBDBM633927(US11807649, Compound 2 | US11807649, Compound 19)
Affinity DataIC50: 15.8nMAssay Description:Table B3: Enzyme-linked immunosorbent assays (ELISA) were performed to measure phosphorylated ERBB2 levels. A capture antibody able to detect phospho...More data for this Ligand-Target Pair
In Depth
Date in BDB:
1/19/2024
Entry Details
US Patent

TargetReceptor tyrosine-protein kinase erbB-2(Human)
Enliven Therapeutics

US Patent
LigandPNGBDBM633927(US11807649, Compound 2 | US11807649, Compound 19)
Affinity DataIC50: 422nMAssay Description:Enzyme-linked immunosorbent assays (ELISA) were performed to measure phosphorylated ERBB2 levels. A capture antibody able to detect phosphorylated an...More data for this Ligand-Target Pair
In Depth
Date in BDB:
12/29/2023
Entry Details
US Patent

TargetEpidermal growth factor receptor(Human)
Enliven Therapeutics

US Patent
LigandPNGBDBM633927(US11807649, Compound 2 | US11807649, Compound 19)
Affinity DataIC50: 450nMAssay Description:Table B4: Enzyme-linked immunosorbent assays (ELISA) were performed to measure phosphorylated EGFR levels using A431 cells (10% FBS). A431 (1.0*104ce...More data for this Ligand-Target Pair
In Depth
Date in BDB:
1/19/2024
Entry Details
US Patent

TargetEpidermal growth factor receptor(Human)
Enliven Therapeutics

US Patent
LigandPNGBDBM633927(US11807649, Compound 2 | US11807649, Compound 19)
Affinity DataIC50: 1.58E+3nMAssay Description:Table B4: Enzyme-linked immunosorbent assays (ELISA) were performed to measure phosphorylated EGFR levels using A431 cells (10% FBS). A431 (1.0*104ce...More data for this Ligand-Target Pair
In Depth
Date in BDB:
1/19/2024
Entry Details
US Patent

TargetReceptor tyrosine-protein kinase erbB-2(Human)
Enliven Therapeutics

US Patent
LigandPNGBDBM633927(US11807649, Compound 2 | US11807649, Compound 19)
Affinity DataIC50: 1.93E+3nMAssay Description:Enzyme-linked immunosorbent assays (ELISA) were performed to measure phosphorylated ERBB2 levels. A capture antibody able to detect phosphorylated an...More data for this Ligand-Target Pair
In Depth
Date in BDB:
12/29/2023
Entry Details
US Patent

TargetEpidermal growth factor receptor(Human)
Enliven Therapeutics

US Patent
LigandPNGBDBM633927(US11807649, Compound 2 | US11807649, Compound 19)
Affinity DataIC50: 1.00E+4nMAssay Description:Enzyme-linked immunosorbent assays (ELISA) were performed to measure phosphorylated EGFR levels using A431 cells (10% FBS). A431 (1.0*104 cells/40 &#...More data for this Ligand-Target Pair
In Depth
Date in BDB:
12/29/2023
Entry Details
US Patent

TargetEpidermal growth factor receptor(Human)
Enliven Therapeutics

US Patent
LigandPNGBDBM633927(US11807649, Compound 2 | US11807649, Compound 19)
Affinity DataIC50: 1.00E+4nMAssay Description:Enzyme-linked immunosorbent assays (ELISA) were performed to measure phosphorylated EGFR levels using A431 cells (10% FBS). A431 (1.0*104 cells/40 &#...More data for this Ligand-Target Pair
In Depth
Date in BDB:
12/29/2023
Entry Details
US Patent